Arnovie101

Arnovie101 is an investigational *in vivo* chimeric antigen receptor T-cell (CAR-T) therapy developed by Circunited BioPharma. Unlike traditional *ex vivo* CAR-T therapies that require complex manufacturing of a patient's cells outside the body, Arnovie101 utilizes an mRNA-lipid nanoparticle (LNP) platform to reprogram T cells directly within the patient's bloodstream. The mRNA encodes a CAR targeting B-lymphocyte antigen CD19, leading to the transient expression of the receptor on endogenous T cells and the subsequent depletion of pathogenic B cells. This approach is being evaluated for the treatment of B cell-mediated autoimmune diseases, specifically systemic lupus erythematosus (SLE) and autoimmune hemolytic anemia (AIHA), offering a potentially more accessible and safer alternative to permanent viral-vector-based cell therapies.